Antiviral compounds
The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
1. A compound, selected from the group consisting of:
N3-(4-Bromo-3-chloro-5-trifluoromethyl-phenyl)-N5-(4-trifluoromethyl-benzyl)-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-furan-2-ylmethyl-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-(5-methyl-furan-2-ylmethyl)-1H-[1,2,4]triazole-3,5-diamine;
N5-(5-Chloro-2-trifluoromethyl-benzyl)-N3-(3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine;
N5-(5-Chloro-pyridin-2-ylmethyl)-N3-(3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine;
(5-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-pyridin-2-yl)-carbamic acid tert-butyl ester;
4-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzoic acid tert-butyl ester;
2-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzoic acid tert-butyl ester;
N5-Benzyl-N3-(3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine;
N5-(6-Amino-pyridin-3-ylmethyl)-N3-(3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-(1-methyl-1H-pyrazol-4-ylmethyl)-1H-[1,2,4]triazole-3,5-diamine;
4-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzoic;
3-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzoic acid;
2-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzoic acid;
N3-(3,5-Dichloro-phenyl)-N5-(4-methanesulfonyl-benzyl)-1H-[1,2,4]triazole-3,5-diamine;
4-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzonitrile;
4-{[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-N,N-dimethyl-benzenesulfonamide;
N-tert-Butyl-4-{[5-(3,5-dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzenesulfonamide;
N5-(3-Chloro-4-trifluoromethyl-benzyl)-N3-(3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-[4-(pyrrolidine-1-sulfonyl)-benzyl]-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-[4-(morpholine-4-sulfonyl)-benzyl]-1H-[1,2,4]triazole-3,5-diamine;
2,6-Dichloro-4-[5-(4-trifluoromethyl-benzylamino)-1H-[1,2,4]triazol-3-ylamino]-benzonitrile;
4-{[5-(3,5-Dichloro-4-cyano-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-methyl}-benzoic acid tert-butyl ester;
4-({5-[6-Chloro-4′-(propane-2-sulfonyl)-2-trifluoromethyl-biphenyl-4-ylamino]-2H-[1,2,4]triazol-3-ylamino}-methyl)-benzoic acid tert-butyl ester;
N3-(3,5-Dichloro-phenyl)-N5-(4-trifluoromethyl-benzyl)-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-(3-trifluoromethyl-benzyl)-1H-[1,2,4]triazole-3,5-diamine;
N3-(3,5-Dichloro-phenyl)-N5-(1-methanesulfonyl-piperidin-4-yl)-1H-[1,2,4]triazole-3,5-diamine;
4-[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-piperidine-1-carboxylic acid tert-butyl ester;
N3-(3,5-Dichloro-phenyl)-N5-piperidin-4-yl-1H-[1,2,4]triazole-3,5-diamine;
1-{4-[5-(3,5-Dichloro-phenylamino)-2H-[1,2,4]triazol-3-ylamino]-piperidin-1-yl}-ethanone; and
N3-(3,5-Dichloro-phenyl)-N5-pyrimidin-5-ylmethyl-1H-[1,2,4]triazole-3,5-diamine.
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable excipient.
3. A method for the treatment of hepatitis C virus infection, comprising the step of administering a therapeutically effective amount of a compound according to claim 1 to a patient in need thereof.